News | December 18, 2025
Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year
This recognition demonstrate excellence in intellectual property (IP) value creation.
This recognition demonstrate excellence in intellectual property (IP) value creation.
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States
The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre
Subscribe To Our Newsletter & Stay Updated
